LCP-Tacro

DRUG4 trials

Sponsors

Veloxis Pharmaceuticals

Conditions

Renal FailureTremors

Phase 3

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

CompletedNCT00817206

Veloxis PharmaceuticalsRenal Failure

Start: 2008-12-31End: 2011-02-28Updated: 2015-09-10

Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx

CompletedNCT01187953

Veloxis PharmaceuticalsRenal Failure

Start: 2010-09-30End: 2014-03-31Updated: 2016-05-18

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)

CompletedNCT01438710

Veloxis PharmaceuticalsRenal Failure, Tremors

Start: 2011-12-31End: 2015-07-31Updated: 2015-10-01

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

CompletedNCT01962922

Veloxis PharmaceuticalsRenal Failure

Start: 2013-11-30End: 2015-08-31Updated: 2018-06-06

Related Papers

Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial

Annals of Transplantation2021-03-055 citations

Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial

Annals of Transplantation2020-07-2810 citations

Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients

American Journal of Kidney Diseases2017-11-2185 citations